Fig. 6

Transgelin-2 regulates cell proliferation in KRAS mutant PDAC cells. a-b. Transgelin-2 was stably silenced by shRNA against tranagelin2 (shRNA-T2) in Capan-1 and Hs 766 T cells. shRNA-NS was used as a control. The cells were then transfected with wild-type (W) or S145A mutant (A) of transgelin-2 for 16 h. The cells were then collected for western blot analysis. c-d. Transgelin-2 was stably silenced by shRNA against tranagelin2 (shRNA-T2) in Capan-1 and Hs 766 T cells. shRNA-NS was used as a control. The cells were then transfected with wild-type (T2-WT) or S145A mutant (T2-S145A) of transgelin-2 for 16 h. Growth curves were plotted based on the number of cells counted every 24 h. *p < 0.05 compared with the shRNA-NS group. e-f. Wild-type (shRNA-T2/T2-WT, n = 6) or S145 mutant (shRNA-T2/T2-S145A, n = 6) of transgelin-2 was overexpressed in transgelin-2 knockdown cells. The cells were then injected subcutaneously into nude mice. Tumor volume was measured at the indicated time points. *p < 0.05 compared with the shRNA-T2/T2-WT group